Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy

Table 3 In-vitro concentrations of 5-AZA-CdR that eradicate proliferative potential of solid tumor cells

Tumor cell lines	IC 50	Duration of treatment	References
HS-SY-II synovial sarcoma	1.3 μM	96 hours	[84]
SYO-1 synovial sarcoma	0.9 μM	96 hours	[84]
KB oropharyngeal cancer	0.5 μM	96 hours	[85]
A549 lung adenocancer	0.49 μM	96 hours	[85]
LoVo colon cancer	0.4 μM	96 hours	[85]
LoVo-DX colon cancer	0.1 μM	96 hours	[85]
MDA-MB- 435 breast cancer	0.2 μM	48 hours	[83]
Hs578T breast cancer	0.13 μM	48 hours	[87]
MCF-7 breast cancer	0.13 μM	48 hours	[87]
MDA-MB- 231 breast cancer	0.013 μM	48 hours	[83]
EMT6 mammary cancer	0.22 μM	18 hours	[60]
Calu-6 lung cancer	0.44 μM	4-8 hours	[60]
A(T1)C1-3 fibrosarcoma	4.38 μM	2 hours	[88]

1 μM= 228 ng/ml. 5-AZA-CdR, 5-Aza-2′-deoxycytidine; IC50, half maximal inhibitory concentration.

ISSN: 1868-7083